All In Biotech

Drug Trial Radar · NCT07341282

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

14

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
McMaster UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Weston Family Foundation
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Conditions

  • Ulcerative Colitis (UC)
  • Primary Sclerosing Cholangitis (PSC)

Interventions

  • Placebo (blinded)Drug

    Identical placebo capsule administered orally twice daily for 4 weeks.

  • Vancomycin (blinded)Drug

    Vancomycin 250 mg administered orally twice daily for 4 weeks.

  • Vancomycin (open-label extension)Drug

    Vancomycin 250 mg administered orally twice daily for 4 weeks (optional extension offered to both arms).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recruitment rateTime frame: 12 months
  2. Retention rateTime frame: 12 months
  3. Treatment adherenceTime frame: 12 months
  4. Protocol compliance with study proceduresTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • McMaster Children's Hospital - Digestive Diseases Clinic

    Hamilton, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.